Microbiotica reported positive Phase Ib data for MB‑310, an oral live biotherapeutic for ulcerative colitis, with 12 of 19 treated patients achieving clinical remission versus 3 of 10 on placebo. Responders sustained remission during a three‑month follow‑up, and histologic markers of mucosal healing improved in treated patients. The company said MB‑310 was generally well tolerated and produced durable responses among those who initially responded. The dataset is limited by size and phase but supports further development; Microbiotica plans next‑stage studies to confirm efficacy and explore biomarker‑guided patient selection. If replicated in larger trials, an oral live biotherapeutic that induces and sustains remission could expand non‑immunosuppressive treatment options in inflammatory bowel disease and attract strategic interest from larger gastroenterology franchises.